Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events.

Journal Article (Journal Article;Review)

Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) improve the risk for heart and kidney failure. However, their effects on major atherosclerotic cardiovascular events (MACE) are less clear. Although outcomes trials of drugs for diabetes were not powered to prove superiority, the totality of trial data yields an estimate of ∼11% relative reduction for MACE (HR 0.89, 95%CI 0.82-0.96) and neutral on stroke (HR 0.92, 95%CI 0.79-1.08). In animal models, SGLT-2i favorably affects plaque size, composition, and inflammatory pathways; human data in this regard are lacking. Ongoing trials are evaluating SGLT-2i efficacy in heart failure, kidney disease, and postmyocardial infarction populations, independent of diabetes status.

Full Text

Duke Authors

Cited Authors

  • Nelson, AJ; Harrington, JL; Kolkailah, AA; Pagidipati, NJ; McGuire, DK

Published Date

  • October 2022

Published In

Volume / Issue

  • 18 / 4

Start / End Page

  • 597 - 607

PubMed ID

  • 36216489

International Standard Serial Number (ISSN)

  • 1551-7136

Digital Object Identifier (DOI)

  • 10.1016/j.hfc.2022.03.007


  • eng

Conference Location

  • United States